Clinical trial
A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With HMGA2-expressing Triple Negative Breast Cancer
NCT04489940 is registered in ClinicalTrials.gov with EMD Serono Research & Development Institute, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With HMGA2-expressing Triple Negative Breast Cancer
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- October 12, 2020
- Completion date
- July 8, 2022
- Enrollment
- 11 (actual)
- Sites
- 45
Conditions
As the registry lists them; a condition with its own page is linked.